Showing 3651-3660 of 5773 results for "".
- Moria Expands its Footprint into Eye Surgery by Acquiring Alchimia SRLhttps://modernod.com/news/moria-expands-its-footprint-into-eye-surgery-by-acquiring-alchimia-srl/2481161/France-based Moria has announced the acquisition of Italian-based company Alchimia SRL, a manufacturer of devices for ophthalmic surgery and human tissue banking. Financial terms of the deal were not disclosed. Founded in 1993, Alchimia has 30 years of expertis
- Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Diseasehttps://modernod.com/news/ocuphire-pharma-hosting-key-opinion-leader-event-on-oral-apx3330-for-diabetic-eye-disease/2481159/Ocuphire Pharma announced that it will host a key opinion leader (KOL) webinar highlighting oral APX3330, its lead drug candidate for diabetic retinopathy (DR) and diabetic macular edema (DME), on Friday, October 14, 2022 at 11 am to 12:30 pm Eastern Time. The event will
- Study Finds Eyenuk Artificial Intelligence Detects Diabetic Retinopathy with Greater Sensitivity than Dilated Examshttps://modernod.com/news/study-finds-eyenuk-artificial-intelligence-detects-diabetic-retinopathy-with-greater-sensitivity-than-dilated-exams/2481158/Eyenuk announced the publication of EyeArt validation results in Ophthalmology Science, a peer-reviewed journal of the American Academy of Ophthalmology. The study, titled “Artifici
- Santen Filing Accepted by EMA for Review of Application for STN1013001 Cationic Emulsion of Latanoprost 50μg/mL in Glaucomahttps://modernod.com/news/santen-filing-accepted-by-ema-for-review-of-application-for-stn1013001-cationic-emulsion-of-latanoprost-50mgml-in-glaucoma/2481157/Santen Pharmaceutical announced European Medicines Agency (EMA) acceptance for review of a marketing authorization application for the use of STN1013001 for lowering of IOP in open-angle glaucoma and ocular hypertension. STN1013001 is preservative-free latanoprost 50μg/mL p
- Paladin Phase 4 Study Confirms Iluvien Patients' Reduced Need for Multiple Treatmentshttps://modernod.com/news/paladin-phase-4-study-confirms-iluvien-patients-reduced-need-for-multiple-treatments/2481156/Alimera Sciences announced that post-hoc analyses from the PALADIN phase 4 safety study demonstrate that median treatment frequency in diabetic macular edema (DME) patients treated with the Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg was lower than from patients on other re
- Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathyhttps://modernod.com/news/aldeyra-therapeutics-achieves-primary-endpoint-in-part-1-of-phase-3-guard-trial-of-adx-2191-in-proliferative-vitreoretinopathy/2481155/Aldeyra Therapeutics announced the achievement of the primary endpoint in Part 1 of the phase 3 GUARD Trial of ADX-2191 (methotrexate injection, USP1) for intravitreal administration, an investigational drug candidate, for the prevention of proliferative vitreoretinopathy (PVR). ADX-21
- New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)https://modernod.com/news/new-data-reveal-molecular-drivers-of-thyroid-eye-disease-ted-may-remain-activated-in-patients-with-low-clinical-activity-score-cas/2481152/Horizon Therapeutics announced the presentation of new data defining molecular patterns in TED and further implicating the role of insulin-like growth factor-1 (IGF-1) in patients with low CAS. These data were presented during the American Academy of Ophthalmology Annual Meeting (
- Cellusion and Minaris Regenerative Medicine Enter into Business Alliance for the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative Therapyhttps://modernod.com/news/cellusion-and-minaris-regenerative-medicine-enter-into-business-alliance-for-the-manufacturing-of-cls001-for-a-corneal-endothelial-cell-regenerative-therapy/2481150/Cellusion, a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem, and Minaris Regenerative Medicine, a global contract and development manufacturing organization, announced a letter of intent (LOI) of the manufacturing of CLS001 for a cor
- Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with XLRPhttps://modernod.com/news/late-breaking-phase-12-data-demonstrates-safety-profile-of-investigational-gene-therapy-botaretigene-sparoparvovec-aav-rpgr-and-sustained-vision-improvement-in-patients-with-xlrp/2481143/MeiraGTx announced the primary results from the phase 1/2 study evaluating the investigational gene therapy botaretigene sparoparvovec (formerly AAV-RPGR) in patients with the inherited retinal disease X-linked retinitis pigmentosa (XLRP) associated with the retinitis pigmentosa GTPase regul
- AAO: Latest Research From the World’s Largest Eye Disease Data Registryhttps://modernod.com/news/aao-latest-research-from-the-worlds-largest-eye-disease-data-registry/2481141/The IRIS Registry (Intelligent Research in Sight) powered several big data studies this year, most of which will be presented and discussed at AAO 2022, the 126th annual meeting of the American Academy of Ophthalmology. &n